Video

Dr. Markman on Timing of BSO in Patients With Ovarian Cancer

Author(s):

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer, or at an increased risk for the disease, should undergo a bilateral salpingo-oophorectomy (BSO).

There is less definitive data on when it is appropriate for patients to undergo a BSO, Markman explains, though the likely age range is between 35 and 45 years old. It may be more fitting to have the procedure at a later age due to side effects associated with BSO, such as surgical menopause, heart disease, osteoporosis, and psychosocial issues.

Additionally, there is increasing evidence that patients with BRCA1/2 mutations will have a very different lifetime risk of ovarian cancer, Markman adds.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center